NASDAQ: LBPH - Longboard Pharmaceuticals, Inc.

Yield per half year: +1.52%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Longboard Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc.

more details
to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-03-12
ISIN US54300N1037
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.longboardpharma.com
Цена ао 59.98
Change price per day: 0% (59.98)
Change price per week: 0% (59.98)
Change price per month: 0% (59.98)
Change price per 3 month: 0% (59.98)
Change price per half year: +1.52% (59.08)
Change price per year: +212.4% (19.2)
Change price per 3 year: +1 078.39% (5.09)
Change price per year to date: 0% (59.98)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 3.44 5
P/E 0 0
EV/EBITDA -2.24 0
Total: 3.13

Efficiency

Title Value Grade
ROA, % -107.35 0
ROE, % -132.99 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0084 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 294.13 10
Yield EPS, % 181.33 10
Total: 8
More

Institutions Volume Share, %
Cormorant Asset Management, LP 2353141 7
FMR, LLC 1649503 4.91
Price (T.Rowe) Associates Inc 1626982 4.84
Farallon Capital Management Llc 1560500 4.64
Polar Capital Holdings PLC 1000000 2.98
Ikarian Capital, LLC 979462 2.91
Integral Health Asset Management, LLC 900000 2.68
Blackrock Inc. 869879 2.59
Point72 Asset Management, L.P. 825000 2.45
Vanguard Group Inc 786433 2.34

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Morningstar Small-Cap Value ETF 0.02069 197.28 2.50476
iShares Morningstar Small-Cap ETF 0.01851 391.25 1.60498
iShares Morningstar Small-Cap Growth ETF 0.01676 596.94 0.72598
0.02395.161.61



Head Job title Payment Year of birth
Mr. Kevin R. Lind President, CEO, Secretary & Director 1.07M 1976 (49 years)
Ms. Brandi L. Roberts CPA, M.B.A. Executive VP & CFO 662.65k 1974 (51 year)
Dr. Randall E. Kaye M.D. Executive VP & Chief Medical Officer 717.95k 1962 (63 years)
Mr. Chadwick J. Orevillo MPH Executive VP & Head of Operations N/A
Mr. Steven W. Spector J.D. Executive VP, Head of Business Development & General Counsel N/A 1965 (60 years)
Dr. Anne M. Danks Ph.D. VP & Head of Nonclinical Research & Development N/A
Mr. Gus Cardenas VP & Head of Quality Assurance N/A
Dr. Marco Peters Ph.D. VP & Head of Translational Science N/A
Dr. Dewey McLin Ph.D. VP & Head of Medical Affairs N/A
Ms. Megan E. Knight VP & Head of Investor Relations

Address: United States, La Jolla. CA, 4275 Executive Square - open in Google maps, open in Yandex maps
Website: https://www.longboardpharma.com